Uncategorized

For the Second Time, AlignRx Makes the Inc. 5000, at No. 1411 in 2024

NEW YORK, August 15, 2024 – Inc. revealed today that AlignRx ranks No. 1411 on the 2024 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy’s most dynamic segment—its independent, entrepreneurial businesses. Microsoft, Meta, Chobani, Under Armour, […]

For the Second Time, AlignRx Makes the Inc. 5000, at No. 1411 in 2024 Read More »

Evaluating the Efficacy and Value Proposition of Modern Diabetic Drugs- Insights for Brokers and Their Groups

As the pipeline of drugs for diabetes management continues to grow, benefit partners and advisors and the employer groups they serve are positioned to influence significant decisions that will impact healthcare spending. With some groups spending millions for diabetic drugs alone, it’s critical to understand the full spectrum of medications available, including newer players like

Evaluating the Efficacy and Value Proposition of Modern Diabetic Drugs- Insights for Brokers and Their Groups Read More »

AlignRx Named Finalist for Best Places to Work in Western New York

Buffalo Business First has named AlignRx as a finalist for its 2024 Best Places to Work awards in the category for companies with 10-24 employees. The results are based on an employee engagement survey that measures six key categories — communication, employee needs, manager effectiveness, personal engagement, team dynamic and trust in leadership. Winners are

AlignRx Named Finalist for Best Places to Work in Western New York Read More »

Stay Informed, Stay Ahead: CVS’s Transition from Humira to Biosimilars

CVS Formulary Change – What You Need to Know  CVS Caremark has announced the removal of Humira from some of their formularies starting the second quarter of 2024. The transition to biosimilar alternatives, which are part of the covered formulary, is planned.   Key Points of the Announcement  Impact Period: Starting April 1, 2024  Affected Parties:

Stay Informed, Stay Ahead: CVS’s Transition from Humira to Biosimilars Read More »

Beyond Unit Cost: Evaluating Clinical Programs and Capabilities of PBMs

Read the full article by AlignRx COO Greg Sanderson on Employee Benefit News.  Drug pricing is typically the main factor brokers and employer groups consider when evaluating PBMs. It makes sense. In a highly complex marketplace, their primary focus is getting their members’ prescriptions filled for the lowest price.   But projecting – and ultimately lowering

Beyond Unit Cost: Evaluating Clinical Programs and Capabilities of PBMs Read More »

AlignRx President & CEO Kevin Kobielski Recognized in 2023 BenefitsPRO Luminaries Awards

BenefitsPRO, the No.1 provider of news, analysis and trends for benefits professionals, has announced its 2023 Luminaries Awards recognizing excellence in the benefits industry. Kevin Kobielski, president & CEO of AlignRx was recognized in the Leadership category.  One of only nine individuals awarded in this category this year, Kevin is featured in the October 2023 issue

AlignRx President & CEO Kevin Kobielski Recognized in 2023 BenefitsPRO Luminaries Awards Read More »

AlignRx Consulting Recognized on the 2023 Inc. 5000 List of Fastest Growing Companies

Inc. revealed today that AlignRx Consulting ranks No. 898 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy’s most dynamic segment — its independent, entrepreneurial businesses.  AlignRx partners with benefit consultants, employer groups, TPAs

AlignRx Consulting Recognized on the 2023 Inc. 5000 List of Fastest Growing Companies Read More »

The Cost Implications of New Weight Loss Treatments for Plan Sponsors

See this article by AlignRx chief pharmacy officer Beckie Fenrick as it originally appeared in BenefitsPRO. With obesity rates in the United States having tripled since the 1980s, the health care system now faces an annual cost of $173 billion due to obesity-related complications, such as heart disease, hypertension, joint pain and certain types of

The Cost Implications of New Weight Loss Treatments for Plan Sponsors Read More »